Search results for "clinical outcome."

showing 10 items of 26 documents

Clinical Severity in Different Waves of SARS-CoV-2 Infection in Sicily: A Model of Smith’s “Law of Declining Virulence” from Real-World Data

2022

Background: The COVID-19 epidemic had a rapid spread worldwide with a continuous and fast mutation of the virus, resulting in the emergence of several variants of concern (VOC). The aim of this study was to evaluate the severity of each VOC among SARS-CoV-2 infected subjects by investigating deaths, ICU admissions, intubations, and severe critical symptoms. Methods: An ecological observational study was performed to evaluate mortality rates and clinical characteristics of 321,490 unvaccinated Sicilian SARS-CoV-2 cases observed from 2 March 2020 to 27 March 2022. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by multivariate logistic regression analysis evaluating factors…

Infectious DiseasesVirologyclinical outcomes COVID-19 epidemiology health care outcome assessment public health SARS-CoV-2
researchProduct

Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study

2018

AbstractPatients with heart failure (HF) are frequently anti-coagulated with vitamin K-antagonists (VKAs). The use of long-acting VKA may be preferable for HF patients due to higher stability of plasma concentrations. However, evidence on phenprocoumon-based oral anti-coagulation (OAC) therapy in HF is scarce. The aim of this study was to assess the impact of the presence of HF on quality of phenprocoumon-based OAC and the subsequent clinical outcome. Quality of OAC therapy and the incidence of adverse events were analysed in a cohort of regular care (n = 2,011) from the multi-centre thrombEVAL study program (NCT01809015) stratified by the presence of HF. To assess the modifiability of outc…

MaleAdministration Oralheart failureclinical outcomeED AMERICAN-COLLEGE030204 cardiovascular system & hematologyTHERAPY ANTITHROMBOTIC THERAPYCohort StudiesPhenprocoumon0302 clinical medicinequality of careGermanyProspective Studies030212 general & internal medicineProspective cohort studyAged 80 and overOUTCOMESIncidenceHazard ratioHematologyTreatment OutcomeCohortFemaleCLINICAL-PRACTICE GUIDELINESSINUS RHYTHMmedicine.drugCohort studyRiskmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHemorrhageWARFARINEJECTION FRACTION03 medical and health sciencesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryWarfarinhealth care modelAnticoagulantsmedicine.diseaseoral anti-coagulationHeart failureATRIAL-FIBRILLATIONPhenprocoumonADVERSE EVENTSbusinessANTICOAGULANT-THERAPY
researchProduct

Maxillary Implant-Supported Overdentures: Mechanical Behavior Comparing Individual Axial and Bar Retention Systems. A Cohort Study of Edentulous Pati…

2020

Background and objectives: To compare the medium- to long-term mechanical behavior of overdentures with two different retention systems: overdentures with Locator&reg

MaleMedicine (General)Dental WearDentistryoverdentureODB++ArticlebarCohort StudiesDental Prosthesis Retentionlocator03 medical and health sciencesR5-9200302 clinical medicinePatient satisfactionSurveys and QuestionnairesmedicineHumansDental Restoration FailureProspective StudiesProspective cohort studyAgedMechanical PhenomenaDental ImplantsEdentulismbusiness.industry030206 dentistrymedicine.diseaseDenture Overlayclinical outcomesTreatment OutcomeScrew looseningPatient SatisfactionAutomotive Engineeringdental implants; overdenture; locator; bar; clinical outcomesFemaleDental Prosthesis Implant-SupportedMouth Edentulousbusiness030217 neurology & neurosurgeryImplant supportedCohort studyFollow-Up StudiesMedicina (Kaunas, Lithuania)
researchProduct

Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papil…

2019

Objectives: To investigate the expression of several immunohistochemical (IHC) markers and their predictive ability for the recurrence-free and progression-free survival of papillary urothelial bladder cancer (UBC) pTa/pT1 G2 (WHO 1973) compared to classical anatomo-clinical variables using a multidimensional analysis. Materials and Methods: A population-based cohort of 213 primary stage UBC (pTa/pT1) G2 (WHO 1973) was evaluated by classic anatomopathological variables and characterized by immunohistochemistry (23 IHC markers, representative of different oncogenic pathways). The most important variables as a predictor of recurrence-free and progression-free survival were selected using mult…

MaleOncologymedicine.medical_specialtyMultidimensional analysisSurvivinUrologyPopulation030232 urology & nephrologyCohort Studies03 medical and health sciences0302 clinical medicineCyclin D1Stage Ta/T1Predictive Value of TestsInternal medicineSurvivinBiomarkers TumormedicineHumansCyclin D1Progression-free survivalStage (cooking)educationCyclin-Dependent Kinase Inhibitor p16AgedNeoplasm Stagingeducation.field_of_studyBladder cancerbiologybusiness.industryClinical outcomeBladder cancerMiddle Agedmedicine.diseaseImmunohistochemistryCarcinoma PapillarySurvival RateKi-67 AntigenUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisKi-67biology.proteinImmunohistochemistryFemaleNeoplasm GradingNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP)

2018

Purpose: To evaluate differences in the characteristics and outcomes of intensive care unit (ICU) patients over time. Methods: We reviewed all epidemiological data, including comorbidities, types and severity of organ failure, interventions, lengths of stay and outcome, for patients from the Sepsis Occurrence in Acutely ill Patients (SOAP) study, an observational study conducted in European intensive care units in 2002, and the Intensive Care Over Nations (ICON) audit, a survey of intensive care unit patients conducted in 2012. Results: We compared the 3147 patients from the SOAP study with the 4852 patients from the ICON audit admitted to intensive care units in the same countries as those…

MaleOriginalEpidemiology[SDV]Life Sciences [q-bio]HSJ UCIlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]MULTICENTERclinical outcomemortality rateCritical Care and Intensive Care Medicineintensive care unitlaw.invention0302 clinical medicineSeverity of diseaselawEpidemiologymiddle agedMedicine and Health SciencesFAILURE030212 general & internal medicineHospital Mortalityintensive care units -- analysis -- epidemiology -- mortalityGeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)CODEScomparative studyintensive careMedicine(all)multilevel analysiIncidenceadultSciences bio-médicales et agricolesIntensive care unit3. Good healthEuropesepsaIntensive Care UnitsfemaleCohortenote intenzivne terapije -- analiza -- epidemiologija -- umrljivostHumanAdultmedicine.medical_specialtyseverity of diseaseCritical CareSepsiIntensive Care UnitUNITED-STATES610 Medicine & healthINTENSIVE-CAREEuropeanArticleSepsisEpidemiology; Sepsis; Severity of disease03 medical and health sciencesAll institutes and research themes of the Radboud University Medical Centerlength of staymaleEpidemiology; Sepsis; Severity of disease; Adult; Europe; Hospital Mortality; Humans; Length of Stay; Male; Critical Care; Intensive Care Units; SepsisAnesthesiologyIntensive careSepsisSCOREmedicineudc:614.2Humanshumanoutcome assessmentSeptic shockbusiness.industrySEPTIC SHOCK030208 emergency & critical care medicineLength of Staymedicine.diseaseTRENDSmajor clinical studySEVERE SEPSIScomorbidity assessmentEmergency medicineEpidemiology; Sepsis; Severity of disease; Critical Care and Intensive Care MedicineObservational studyCLAIMSbusinessSepsis;Severity of disease;Epidemiologyresnost bolezni
researchProduct

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

2011

Abstract Marginal zone B-cell lymphomas (MZLs) have been divided into 3 distinct subtypes (extranodal MZLs of mucosa-associated lymphoid tissue [MALT] type, nodal MZLs, and splenic MZLs). Nevertheless, the relationship between the subtypes is still unclear. We performed a comprehensive analysis of genomic DNA copy number changes in a very large series of MZL cases with the aim of addressing this question. Samples from 218 MZL patients (25 nodal, 57 MALT, 134 splenic, and 2 not better specified MZLs) were analyzed with the Affymetrix Human Mapping 250K SNP arrays, and the data combined with matched gene expression in 33 of 218 cases. MALT lymphoma presented significantly more frequently gain…

MalePathologyLymphomaMarginal ZoneBiochemistryExtranodal Diseaseclassification/genetics/pathologyhemic and lymphatic diseases80 and overgeneticsAged 80 and overComparative Genomic HybridizationGenomeMALT lymphomaHematologySingle NucleotideMiddle AgedMarginal zonePrognosisGene Expression Regulation NeoplasticAdult Aged Aged; 80 and over Chromosome Aberrations Comparative Genomic Hybridization DNA Fingerprinting Female Gene Expression Profiling Gene Expression Regulation; Neoplastic Genome; Human Humans Lymphoma; B-Cell; Marginal Zone; classification/genetics/pathology Male Middle Aged Polymorphism; Single Nucleotide; genetics Prognosis Splenic Neoplasms; classification/genetics/pathology Young AdultFemaleHumanAdultmedicine.medical_specialtyGenome-wide DNA profilingImmunologyBiologyPolymorphism Single NucleotideYoung AdultGenome-wide DNA profiling; marginal zone lymphomas; clinical outcome.medicineSNPHumansSplenic marginal zone lymphomaPolymorphismAgedChromosome AberrationsNeoplasticGenome HumanSplenic Marginal Zone Lymphoma; GenomicGene Expression ProfilingSplenic NeoplasmsB-CellLymphoma B-Cell Marginal ZoneCell Biologyclinical outcome.medicine.diseasemarginal zone lymphomaDNA FingerprintingLymphomaGene expression profilingGene Expression RegulationComparative genomic hybridization
researchProduct

Outcomes of chronic total occlusion percutaneous coronary intervention in patients with reduced left ventricular ejection fraction.

2022

Background: The relationship between left ventricular ejection fraction (LVEF) and the success and safety of coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has received limited study. Methods: We examined the clinical characteristics and outcomes of CTO PCI in the Prospective Global Registry for the Study of CTO Intervention (PROGRESS-CTO) after stratifying patients by LVEF (≤35%, 36%–49%, and ≥50%). Results: A total of 7827 CTO PCI procedures with LVEF data were included. Mean age was 64 ± 10 years, 81% were men, 43% had diabetes mellitus, 61% had prior PCI, 45% had prior myocardial infarction, and 29% had prior coronary artery bypass graft surgery. Technic…

Maleclinical outcomeAftercareleft ventricular ejection fractionStroke VolumeGeneral MedicineMiddle AgedCoronary AngiographyPatient DischargeVentricular Function LeftPercutaneous Coronary InterventionTreatment OutcomeCoronary OcclusionRisk FactorsChronic DiseaseHumansRadiology Nuclear Medicine and imagingFemaleProspective StudiesCardiology and Cardiovascular Medicinechronic total occlusionAgedCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventionsREFERENCES
researchProduct

Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility

2020

Abstract Background The Sars-CoV-2 can cause severe pneumonia with multiorgan disease; thus, the identification of clinical and laboratory predictors of the progression towards severe and fatal forms of this illness is needed. Here, we retrospectively evaluated and integrated laboratory parameters of 45 elderly subjects from a long-term care facility with Sars-CoV-2 outbreak and spread, to identify potential common patterns of systemic response able to better stratify patients’ clinical course and outcome. Methods Baseline white blood cells, granulocytes’, lymphocytes’, and platelets’ counts, hemoglobin, total iron, ferritin, D-dimer, and interleukin-6 concentration were used to generate a …

Malemedicine.medical_specialtyLymphocyteIronlcsh:MedicineDiseaseMonocyteGeneral Biochemistry Genetics and Molecular BiologyMonocytesFibrin Fibrinogen Degradation ProductsLeukocyte CountLong-term care facilitieInternal medicineD-dimermedicineHumansLymphocytesAgedRetrospective StudiesAged 80 and overbiologybusiness.industryPlatelet CountLong-term care facilitiesClinical outcomeSARS-CoV-2MonocyteResearchlcsh:RCOVID-19Retrospective cohort studyGeneral MedicineBiomarkerMiddle Agedmedicine.diseasePrognosisLong-Term CareFerritinPneumoniamedicine.anatomical_structureTreatment OutcomeD-dimerbiology.proteinFemaleLymphocyteHemoglobinbusinessBiomarkers
researchProduct

Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

2022

[Objective] To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

Maleprogressive multifocal leukoencepdiarrheacholinergic receptorplasma exchangemiddle agedadultimmunologic factornauseaanemiahypertrichosisageddrug withdrawaldiabetes mellitusdisease severityTRIALsafetycorticosteroidhypertensionImmunologyMiastenia gravismethotrexateArticlebulbar paralysispancytopeniaMuscular DiseasescompulsionMyasthenia Gravischolinesterase inhibitorcross-sectional studyHumansImmunologic FactorshumanRITUXIMABarthralgiaNeurologíaMalalties muscularsAgedRetrospective Studiesmyasthenia gravisleukopeniaabdominal painDrug testingmajor clinical studyCross-Sectional StudiesDrug side effectscyclophosphamideobservational studyNeurology (clinical)immunoglobulinFEATURESefficacyclinical outcomeelectrophysiological procedurescomputer assisted tomographyDOUBLE-BLINDTratamiento médicorituximabOutcome Assessment Health CareImmunologiamuscle specific tyrosine kinaseRegistriestacrolimusazathioprineMedicamentoGeneral Neurosciencenephrotoxicitygeneral condition deteriorationhyperplasiatrialMiddle Agedliver toxicitydrug toxicityunclassified drugfemaleEfectes secundaris dels medicamentsSAFETYFemaledouble-blindheadacheblindnessAdultAssaigs clínics de medicamentsmalefeaturesfollow uppneumoniacyclosporinemycophenolate mofetilprotein tyrosine kinaseimmunosuppressive agentallergyalopeciaEFFICACYclinical featureosteopeniaSpainprednisonehyperglycemiaautoantibodyFollow-Up Studies
researchProduct

Multi-spectral Pattern of Clinical Presentation and the Resultant Outcome in Central Nervous System Tuberculosis: A Single Center Study on the Ubiqui…

2020

Central nervous system (CNS) tuberculosis (TB) is a great medical masquerader having a multi-spectral pattern of clinical presentation, thereby complicating early diagnosis and appropriate management. This review article describes clinical presentation of CNS TB in a group of 47 patients, who were managed in the Nobel Medical College and Teaching Hospital in Biratnagar, Nepal during the last 2 years. We evaluated demographic profile, mode of management, and clinical outcome in these patients. The findings were that intracranial TB was present in 27 (57.5%) patients and the spinal involvement was in 20 (42.5%) patients. The most frequent presentation of the former was TB meningitis with hydr…

Pediatricsmedicine.medical_specialtyTuberculosisClinical outcomebusiness.industryDifferential diagnosimedicine.diseaseSingle CenterHydrocephalusReview articleMeningiti03 medical and health sciences0302 clinical medicineCentral nervous systemPott’s spinemedicineTuberculosis030212 general & internal medicinePresentation (obstetrics)Differential diagnosisbusinessAbscessMeningitis
researchProduct